XENE
Xenon Pharmaceuticals Inc
NASDAQ: XENE · HEALTHCARE · BIOTECHNOLOGY
$55.75
+2.24% today
Updated 2026-04-29
Market cap
$5.39B
P/E ratio
—
P/S ratio
718.38x
EPS (TTM)
$-4.36
Dividend yield
—
52W range
$28 – $64
Volume
1.5M
Xenon Pharmaceuticals Inc (XENE) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-4,974.00%
ROE
-51.80%
ROA
-32.60%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2011 | $6.92M | $-11.99M | 100.00% | -175.11% | -173.34% |
| 2012 | $14.31M | $-4.30M | 48.84% | -22.04% | -30.06% |
| 2013 | $27.36M | $12.03M | 77.30% | 35.50% | 43.98% |
| 2014 | $28.37M | $13.02M | 79.19% | 39.15% | 45.89% |
| 2015 | $15.58M | $-15.75M | 100.00% | -60.10% | -101.12% |
| 2016 | $1.80M | $-23.00M | 38.21% | -1,376.43% | -1,275.49% |
| 2017 | $311000.00 | $-30.70M | -8,122.83% | -10,474.28% | -9,872.67% |
| 2018 | $0.00 | $-34.50M | — | — | — |
| 2019 | $6.83M | $-41.59M | 100.00% | -627.02% | -609.09% |
| 2020 | $32.17M | $-28.84M | 100.00% | -97.31% | -89.65% |
| 2021 | $18.44M | $-78.88M | 100.00% | -428.45% | -427.85% |
| 2022 | $9.43M | $-125.37M | 100.00% | -1,368.91% | -1,328.95% |
| 2023 | $0.00 | $-182.39M | — | — | — |
| 2024 | $0.00 | $-234.33M | — | — | — |
| 2025 | $7.50M | $-345.91M | 66.09% | -4,974.27% | -4,612.13% |